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Haemolytic uraemic syndrome (HUS) is a clinical entity deﬁned as the triad of nonimmune
haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying
lesions are mediated by systemic thrombotic microangiopathy (TMA). Different causes can
induce the TMA process that characterises HUS. In this document we consider atypical
HUS (aHUS) a sub-type of HUS in which the TMA phenomena are the consequence of
the  endotelial damage in the microvasculature of the kidneys and other organs due to a
disregulation of the activity of the complement system. In recent years, a variety of aHUs-
related mutations have been identiﬁed in genes of the complement system, which canculizumab
omplement
hrombotic microangiopathy
explain approximately 60% of the aHUS cases, and a number of mutations and polymor-
phisms have been functionally characterised. These ﬁndings have stablished that aHUS is a
consequence of the insufﬁcient regulation of the activation of the complement on cell sur-
faces, leading to endotelial damage mediated by C5 and the complement terminal pathway.
 Please cite this article as: Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. Actualización en síndrome hemolítico
rémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrologia. 2015;35:421–447.
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Eculizumab is a monoclonal antibody that inhibits the activation of C5 and blocks the gen-
eration of the pro-inﬂammatory molecule C5a and the formation of the cell membrane
attack complex. In prospective studies in patients with aHUS, the use of Eculizumab has
shown a fast and sustained interruption of the TMA process and it has been associated
with signiﬁcative long-term improvements in renal function, the interruption of plasma
therapy and important reductions in the need of dialysis. According to the existing literature
and  the accumulated clinical experience, the Spanish aHUS Group published a consensus
document with recommendations for the treatment of aHUs (Nefrologia 2013;33[1]:27–45).
In the current online version of this document, we update the aetiological classiﬁca-
tion of TMAs, the pathophysiology of aHUS, its differential diagnosis and its therapeutic
management.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Actualización  en  síndrome  hemolítico  urémico  atípico:  diagnóstico  y
tratamiento.  Documento  de  consenso
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Microangiopatía trombótica
r  e  s  u  m  e  n
El síndrome hemolítico urémico (SHU) es una entidad clínica deﬁnida por la tríada ane-
mia  hemolítica no inmune, trombocitopenia e insuﬁciencia renal aguda, en la que las
lesiones subyacentes están mediadas por un proceso de microangiopatía trombótica (MAT)
sistémico. Distintas causas pueden desencadenar el proceso de MAT que caracteriza el
SHU. En este documento consideramos SHU atípico (SHUa) como el subtipo de SHU en
el  que los fenómenos de MAT son fundamentalmente consecuencia del dan˜o producido
en  el endotelio de la microvasculatura renal y de otros órganos por desregulación de la
actividad del sistema del complemento. En los últimos an˜os se han identiﬁcado diversas
mutaciones en genes del sistema del complemento asociados a SHUa, que explicarían
aproximadamente el 60% de los casos de SHUa, y se han caracterizado funcionalmente
numerosas mutaciones y polimorﬁsmos asociados a SHUa que han permitido determinar
que la patología se produce como consecuencia de la deﬁciente regulación de la activación
del  complemento sobre las superﬁcies celulares y que lleva al dan˜o endotelial mediado por
la  activación del C5 y de la vía terminal del complemento. Eculizumab es un anticuerpo
monoclonal humanizado que inhibe la activación del C5, bloqueando la generación de la
molécula proinﬂamatoria C5a y la formación del complejo de ataque de membrana. En
estudios prospectivos en pacientes con SHUa su administración ha demostrado la inter-
rupción rápida y sostenida del proceso de MAT, con una mejora signiﬁcativa de la función
renal a largo plazo y una reducción importante de la necesidad de diálisis y el cese de
la  terapia plasmática. En función de las evidencias cientíﬁcas publicadas y la experiencia
clínica acumulada, el Grupo Espan˜ol de SHUa publicamos un documento de consenso con
recomendaciones para el tratamiento de la enfermedad (Nefrología 2013;33(1):27–45). En la
presente versión online del documento se actualizan los contenidos sobre la clasiﬁcación
etiológica de las MAT, la ﬁsiopatología del SHUa, su diagnóstico diferencial y su manejo
terapéutico.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Haemolytic uraemic syndrome (HUS) is a clinical entity
consisting of the triad of nonimmune microangiopathic
haemolytic anaemia, thrombocytopenia, and acute renal
failure.1 The histological lesions of HUS typically involvesystemic thrombotic microangiopathy (TMA), largely resulting
in impaired intrarenal vessels. A greater number of HUS cases
are caused by a Shiga toxin-producing (STEC) Escherichia coli
enteric infection or verotoxin-producing (VTEC) germs,
resulting in the so-called typical HUS or STEC (VTEC)-HUS.
Genetic or acquired (autoantibodies) dysregulation of the
alternative complement pathway leading to endothelial
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amage and systemic TMA  phenomena occur in nearly
0% of HUS reports.2 This kind of HUS related to the
omplement dysregulation is known as atypical HUS
aHUS).
In 2011, Eculizumab (Soliris®; Alexion Pharmaceut-
cals, Connecticut, USA) was approved by the American
nd European regulatory agencies for the treatment of
HUS.3 Eculizumab is a humanised monoclonal antibody
nhibiting C5 activation and blocking the production of the
roinﬂammatory C5a anaphylatoxin, as well as the formation
f the membrane-attack complex, leading to cell lysis.4 In
rospective studies conducted in aHUS patients, Eculizumab
ffectively halted the TMA  process and its effects, and was
ssociated with the rapid, signiﬁcant, and long-term improve-
ent of haematological and renal function abnormalities,5
nd with improved systemic involvement and high blood
ressure.
In 2012, the Spanish Group for aHUS gathered to develop a
onsensus document including recommendations for treat-
ng the disease.6 The group has been meeting every year
ver since then in order to update both the understanding
f the various aspects of interest related to the dis-
ase (including the aetiological classiﬁcation of TMAs, the
athophysiology of aHUS, and companion diagnostics) and
reatment recommendations based on already published
ig. 1 – Renal histopathological lesions from haemolytic uraemic
esangiolysis (C) Thrombi in the glomerular capillaries (arrow). 
ourtesy of Dr. R. Ortega (Histopathology department of the Hosp(5):421–447 423
scientiﬁc evidence and clinical experience. The contents orig-
inally published in Nephrology 2013;33(1):27–45 have been
updated in the current online version of the consensus
document.
Aetiological  classiﬁcation  of  thrombotic
microangiopathies
The term TMA describes a histological lesion of the arte-
rioles and capillaries resulting in thickened and swollen
vessel walls, detachment of endothelial cells, widening of
the subendothelial space caused by the build-up of proteins
and cell lysis material, and the presence of platelet thrombi
obstructing vascular lumen (Fig. 1).1 Two clinical entities with
different aetiology and pathophysiology are characterised by
primary TMA lesions: thrombotic thrombocytopenic purpura
(TTP) and HUS.
Intravascular thrombosis in TTP results from a severe deﬁ-
ciency in the metalloprotease activity of the A Desintegrinthe ultra-large multimers of the Von Willebrand factor.7 This
deﬁciency may be genetic or acquired via IgG circulating
 syndrome. (A) Ischaemic and retracted glomeruli. (B)
(D) Artery occluded by platelet thrombi. Photographs
ital Universitario Reina Sofía, Córdoba).
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incidence of aHUS in the US has been estimated to be of
36424  n e f r o l o g i a. 2
antibodies blocking ADAMTS13 (particularly in patients
receiving platelet antiaggregants).8
Ninety percent of HUS cases are caused by a STEC enteric
infection resulting from contaminated food (typical HUS or
STEC [VTEC]-HUS).2 The Shiga toxin causes a direct injury
on the vascular endothelium, triggering a number of cell
and vascular events which ultimately lead to TMA.2 Clinical
presentation usually involves abdominal pain and diarrhoea,
together with acute renal failure within 4–10 days. Prognosis
is typically favourable, with a mortality rate below 5% and 80%
of patients achieving complete clinical recovery, although pro-
gression to severe chronic renal failure is observed over time
in up to 20–30% of patients.9,10
aHUS is essentially diagnosed by exclusion once
ADAMTS13 (TTP) deﬁciency or STEC infection (STEC-HUS)
are ruled out. In patients with aHUS, TMA phenomena
are a consequence of the dysregulation of the alternative
complement pathway on the cell surface. This abnormal-
ity results in uncontrolled activity on own cells following
complement activation (by several triggering factors), lead-
ing to endothelial damage, inﬂammation, and secondary
thrombosis, with an increasing number of cases involving
genetic or acquired factors. Mutations have been described
in one or more  complement proteins in nearly 60% of over
1000 patients with reports of aHUS in the literature,11–18
although a genetic component (involving complement genes
or other, including coagulation genes) and/or unspeciﬁed
autoimmunity may also be present in the remaining patients.
Of note, anti-Factor H (FH) autoantibodies have been found
in 5–10% of aHUS patients.19 Unlike STEC-HUS, which is
usually an isolated event, aHUS is a chronic and relaps-
ing entity triggered by the uncontrolled activation of the
complement system. Before Eculizumab became available,
aHUS had been mostly associated with a poor prognosis: the
mortality rate following a ﬁrst episode of aHUS was 10–15%,
and renal function remained unrecovered in up to 50% of
patients.11,12,20
A type of aHUS resulting from recessive mutations in the
DGKE gene coding for the DGK- (diacylglycerol kinase-) pro-
tein has recently been described.21 The loss of this enzyme
activity in endothelial cells, platelets, and podocytes leads to
endothelial cells apoptosis and impaired angiogenic response,
thereby resulting in a prothrombotic and inﬂammatory
state.22 Patients with DGKE mutations exhibit various pheno-
types ranging from aHUS to membranoproliferative glomeru-
lonephritis with high proteinuria and nephrotic syndrome.23
aHUS patients develop persistent high blood pressure and
haematuria-proteinuria (including in the nephrotic range) in
their ﬁrst year of life. Unlike paediatric aHUS associated with
complement genetic alterations, progression to chronic renal
disease among these patients is not sudden, but develops over
years.21
In addition to STEC enteric infection (typical HUS),
abnormalities in the regulation of complement activation,
mutations in DGKE or coagulation genes (aHUS), or (genetic
or autoimmune) deﬁciency of ADAMTS13 in TTP, there are
many other factors and clinical entities that may be asso-
ciated with the development of TMA. This kind of TMA
is included under the term secondary TMA. Some cases
reported in children are associated with methylmalonic;3 5(5):421–447
aciduria24 or more  commonly (5% of HUS reports in chil-
dren) with neuraminidase-producing invasive Streptococcus
pneumoniae infections (resulting in the exposure of the crypto-
antigen T in the cell surface and unleashing the TMA
phenomenon),25 or H1N1 infection.26 TMA  has been gener-
ally associated with viral infections (CMV, HIV, parvovirus),
neoplastic processes, drugs (antitumor agents, including the
vascular endothelial growth factor inhibitors, immunosup-
pressants such as calcineurin inhibitors [cyclosporine and
tacrolimus] or the mammalian target of rapamycin inhibitors
[mTOR; sirolimus, everolimus], platelet antiaggregants, antivi-
rals, or oral contraceptive drugs), malignant high blood
pressure, bone marrow or solid organ transplantation, preg-
nancy and postpartum, autoimmune systemic diseases, or
glomerulonephritis.27
Importantly, the foregoing causes of TMA may not always
be identiﬁed in all patients, whereas some may present
more than one aetiology, resulting in a heterogeneous pre-
sentation and a challenging diagnosis. In fact, overlapping
entities are common and up to 25% of patients with STEC-
HUS and 86% of patients with pregnancy-associated HUS
develop complement system mutations, where aHUS is actu-
ally the underlying disease.28,29 Mutations in the complement
system have also been reported in post-transplant HUS asso-
ciated with the use of calcineurin inhibitors and in HUS
related to autoimmune diseases in 27% and 33% of patients,
respectively.12 Furthermore, several cases of secondary TMA
have been reported to date with successful treatment out-
comes with Eculizumab (TMA associated with drugs,30 solid
organs31 or bone marrow32 transplantation, pregnancy33 and
systemic erythematous lupus34). The fact that complement
blockade (by Eculizumab) is associated with a favourable
clinical response and the reversibility of TMA  suggests the
potential and important role of non-genetic complement dys-
regulation in many  cases of secondary TMA, predisposing
patients to its development. On this basis, Fig. 2 sum-
marises the proposed aetiological classiﬁcation of TMAs and
illustrates the potential overlapping between these clinical
entities. The classiﬁcation of TMAs should be understood
as a current topic of interest and major debate is tak-
ing place among the medical community as a result of
the continuous progress made in the understanding of the
pathophysiology of these entities.35 Given that the aHUS
mediated by complement dysregulation is the main reason
for debate, only this entity will be discussed in the following
sections.
Atypical  haemolytic  urinary  syndrome:
a clinical  entity
Epidemiology
aHUS is considered an ultra-rare disease. Data available on its
incidence and prevalence are limited, as well as the knowl-
edge of the actual epidemiology of the disease. The annual∼1–2 cases/million inhabitants. A recent multicentre study
in Europe reported an incidence of 0.11 cases/million inhabi-
tants. According to the European Medicines Agency (EMA), the
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TTP (ADAMTS13 activity <5-10%
- Genetic cause
- Antibodies
TTP
Secondary
TMAs
aHUS
(associated with
complement)
Shiga toxin-producing Escherichia coli
- Strain 0157:H7 and other strains
- Shigella disenteriae type I
- Streptococcus pneumoniae (neuraminidase)      
Complement abnormalities
- Mutations in FH, MCP, FI
THBD, FB and C3
- Polymorphism risk in FH and MCP
- Anti-FH antibodies 
 STEC- HUS
 and STEC-like
Pregnancy 
- Pre-eclampsia and eclampsia   - Anti-tumour
- HELLP syndrome                         - Mitomycin C.
- Postpartum TMA                          Gemcitabine, Cisplatin
Systemic diseases                            - VEGF and tyrosine kinase        
- SLE                                                inhibitors (sunitinib,
- Vasculitis                                                imatinib and dasatinib)
- Scleroderma                          - Everolimus
- Anti-phospholipid syndrome    - Radiation
Glomerulonephritis  - Others 
- C3 Glomerulopathies                               - Quinine 
- Glomerulopathies associated with           - Interferon
monoclonal gammapathies   - Ticlopidine and clopidogrel
of uncertain significance                          - Valaciclovir
- IgA nephropathy                          - Oral contraceptives
Malignant arterial hypertension  Bone marrow transplant 
Infections                                             Solid organ transplant
- HIV                                                - Drugs
- HCV                                                Immunosuppressants
- H1N1 (influenza A)                          - Humoral rejection 
- Others
Neoplasms                                                           
Drugs/treatments                               
- Immunosuppressants                                 
  - Calcineurin inhibitors                             
  (cyclosporine, tacrolimus) 
  - mTOR inhibitors 
  (sirolimus, everolimus) 
   - Viral infections (CMV and 
   BK virus)
 Other causes of TMA
- Methylmalonic aciduria
   - Intestinal lymphangiectasis  
Fig. 2 – Classiﬁcation of the aetiologies of thrombotic microangiopathies. ADAMTS13: A Disintegrin And Metalloproteinase
with a ThromboSpondin type 1 motif, member 13;  aHUS: atypical haemolytic uraemic syndrome; CMV:  cytomegalovirus; FB:
complement factor B; FH: complement factor H; FI: complement factor I; HCV: hepatitis C virus; HELLP: Hemolysis, Elevated
Liver enzymes, Low Platelet count; HIV: human immunodeﬁciency virus; HUS: haemolytic uraemic syndrome; MCP:
membrane cofactor protein; mTOR: mammalian target of Rapamycin; SEL: systemic erythematous lupus; STEC: Shiga
toxin-producing Escherichia coli; THBD: thrombomodulin; TMA: thrombotic microangiopathy; TTP: thrombocytopenic
thrombotic purpura; VEGF: vascular endothelial growth factor.
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mong patients below the age of 18, with lower rates among
dults.
Children and adults are predominantly affected by aHUS,
lthough it may develop at any time in life.11,12 The onset of the
isease usually occurs before the age of 18 (60% vs. 40%) and
ex characteristics are well-balanced (women are primarily
ffected when the disease is developed in adulthood).11,13
linical  presentation
linical onset is often abrupt, although 20% of patients may
evelop it progressively (in weeks or months), accompanied by
ubclinical anaemia, ﬂuctuating thrombocytopenia, and pre-
erved renal function.11 The clinical picture comprises the
riad of nonimmune microangiopathic haemolytic anaemia,
1hrombocytopenia, and acute renal failure. High levels
f lactate dehydrogenase (LDH), undetectable haptoglobin
nd schistocytes conﬁrm the presence of intravascular
emolysis20 associated with haematuria, proteinuria, and/oracute renal failure (with or without oligoanuria). High blood
pressure resulting from volume overload or vascular lesion is
common.1 In some patients, the single manifestation of TMA
may be proteinuria with high blood pressure and progressive
renal failure without haematological abnormalities.
Even though aHUS lesions are predominantly observed
in renal vessels, the diffuse and systemic nature of the
TMA phenomenon leads to the involvement of the microvas-
culature of other organs (including, but not limited to
the brain, heart, intestine, pancreas, and lungs),1 therefore
accounting for common extrarenal symptoms.11,12 Neuro-
logical symptoms are the most common (48%),37 including
irritability, somnolence, confusion, convulsions, encephalo-
pathy, stroke, hemiparesis, visual abnormalities, hemiplegia,
and coma.1,12,37,38 Myocardial infarction has been described
in up to 3% of aHUS patients in relation to sudden death.12,39Myocardiopathy, heart failure, and peripheral ischaemic
vasculopathy have also been reported,19,37,40,41 as well as
diarrhoea (30%) and other digestive symptoms (including,
but not limited to colitis, nausea, vomit, abdominal pain,
 0 1 5;3 5(5):421–447
Table 1 – Risk factors in atypical uraemic haemolytic
syndromea
Mutations
Loss of function
CFH (∼13%)
MCP (∼11%)
CFI (∼10%)
THBD (∼4%)
Gain of function
C3 (∼4%)
CFB (∼3%)
Polymorphisms
Increasing risk
CFH: c.-332C>T; c.2016A>G (p.Gln672Gln); c.2808G>T
(p.Glu936Asp)
MCP: c.-652A>G; c.-366A>G; c.989-78G>A; *897T>C
Providing protection
CFH: c.184G>A (p.Val62Ile)
Autoantibodies
Anti-FH (∼5%)
Environmental factors
Infections
Immunosuppressants
Oral contraceptives
Anti-cancer drugs
Anti-FH: anti-complement factor H antibody; CFB:  complement fac-
tor B gene; CFH:  complement factor H gene; CFI:  complement factor
I gene; MCP:  membrane cofactor protein. Gene; THBD: thrombomo-
dulin gene.
a “Multiple hits” theory. aHUS is a complex disease normally involv-
ing various risk, genetic, and environmental factors. Patients are
commonly carriers of more than one mutation in complement
genes or combined mutations with risk polymorphisms. Envi-
ronmental factors are also necessary to help reveal the genetic
disposition from mutations or polymorphisms. Concomitant
mutations with risk polymorphisms, autoantibodies, or trigger-
ing environmental factors account for the incomplete penetrance
of aHUS, as well as for the differences in its presentation and
progression among carriers of complement gene mutations.426  n e f r o l o g i a. 2
hepatitis, cholestasis, and pancreatitis).12,19,38,42 Skin involve-
ment including ulcer lesions in lower limbs has recently been
reported in aHUS patients.43 Heterogeneity of symptoms has
posed a challenge for companion diagnostics of other causes
of TMA.
Pathophysiology
The complement system, consisting of several circulating
plasma and membrane-associated proteins, is part of innate
immunity and is vital for ﬁghting infections, processing
immune complexes, antibody response, and the elimina-
tion of apoptotic residues. Activation by any of the existing
pathways (classical, lentin, and alternative) leads to the for-
mation of multiprotein complexes with C3-convertase activity
splitting the C3 protein and resulting in C3b (Fig. 3). The
covalent binding of this molecule to the surfaces activating
the complement favours phagocytosis by polymorphonuclear
leukocytes and macrophages, therefore resulting in activated
C5, directing the attack complex to the membrane and caus-
ing cell lysis. In addition, the resulting C3b leads to a rapidly
enhanced complement activation by promoting the formation
of further C3-convertases, since it is one of the compo-
nents of C3-convertase of the alternative pathway.44 In order
to avoid total uptake by complement activation, as well as
damage to self tissues (C3b binds indiscriminately to both
pathogens and self cells), a number of process-regulating
proteins, such as FH, the membrane cofactor protein (MCP),
and complement factor I (FI) dissociate C3-convertases and
result in C3b degradation. C3b levels, therefore, remain low
under normal conditions and they build up following com-
plement activation only in the structures related to this
activity.
Several studies have shown that around 60% of aHUS
patients are carriers of mutations in complement-regulating
genes (CFH, MCP, CFI, thrombomodulin [THBD], or in the com-
ponents of C3-convertase, factor B [FB], and C3).45–54 All these
mutations cause the dysregulation of the alternative pathway
(Table 1). FH acts in plasma by controlling complement
homeostasis and in cell surfaces by preventing damage to self
components. Mutations in the C-terminal region of FH are
characteristic of aHUS. Because the altered FH region medi-
ates complement activation in cell surfaces, cell protection
against accidental damage resulting from complement acti-
vation is decreased by these mutations, with no involvement
of complement regulation in plasma.55 The functional assay
of aHUS-associated mutations found in other complement
genes, including MCP, CFI, CFB or C3,  has also conﬁrmed that
all of them result in a defective protection of cell surfaces
and this loss of complement regulation may be due to the
decreased activity of regulating proteins or to the abnormally
high activity of C3-convertases. Thus, while the regulatory
activity of these proteins is impaired by mutations in FH, MCP,
and FI, mutations in FB or C3 result in further activation of the
C3-convertase.Around 5–10% of aHUS patients develop anti-FH antibodies
targeted to the C-terminal region, with similar effects to those
observed in FH mutations.56,57 Their role in the pathogenesis
of aHUS has not been fully established, but seems to beassociated with disease onset or recurrence. Given that anti-
body titres may decrease over time, they should be screened
early in the course of aHUS. Anti-FH antibodies are associated
with complement factor H-related protein 1 deﬁciency (FHR1)
in patients with aHUS.58
Penetrance of aHUS in carriers of mutations in some genes
is around 50%, with only a few carriers from families with
identiﬁed mutations commonly developing aHUS and show-
ing a variable clinical presentation. Clinical heterogeneity,
which results from the existence of additional (genetic and
environmental) risk factors mediating the development and
the outcome of the disease, is largely observed among unre-
lated carriers of this mutation. Screening for complement
mutations in aHUS patients and conducting case-control stud-
ies based on genetic polymorphisms in candidate genes or
genetic markers in the human genome has allowed for the
identiﬁcation of some variants (polymorphisms) in CFH and
MCP  genes modulating the penetrance and severity of the dis-
ease (Table 1).49,59,60
Haplotypes CFH-H3 and MCPggaac are the most rele-
vant polymorphisms associated with the risk of aHUS. Both
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Classic and
lectins pathway
C3-convertase 
(C4b2a)
C3-convertase
(C3bBb) 
 Alternative
pathways
aHUS 
mutations
Cell
membrane
Eculizumab
C3
C3b
(formation)
(activation) (C5-convertase)
MAC
C5-9
FH
MCP
FI
C3b
FB
C3
C5
Lytic pathway
Fig. 3 – Complement dysregulation in atypical haemolytic uraemic syndrome. Complement activation by any of the 3
pathways (detection of foreign antigens, alternative pathway; of antibodies, classical; or mannan polysaccharides, lectin)
leads to the build-up of large quantities of C3b on the activator cell membrane, causing opsonisation and C5 activation
(terminal or lytic pathway), resulting in the formation of the membrane attack complex and cell lysis. Complement
activation results in inﬂammation and leucocyte recruitment. The key process in complement activation is C3b formation,
which depends on unstable enzymatic complexes – C3-convertases – catalysing the rupture of C3 to create C3b. In turn, C3b
has the ability to form further C3-convertase of the alternative pathway (C3bBb), thus enhancing the initial activation. The
mediation of C3B production is two-fold: dissociation of C3-convertases and proteolytic inactivation of C3b and C4b. Several
regulatory proteins in plasma and the cell membrane carry out this regulatory activities, including, factor H, MCP  and factor
I, which play an essential role in the dissociation of C3-convertase of the alternative pathway (C3bBb) and the proteolytic
degradation of C3b. Mutations in these proteins found in patients with aHUS interfere with this regulatory activity of the
alternative pathway activation. Some patients with aHUS are carriers of mutations in proteins C3 and factor B organising
C3-convertase. These mutations are particular, as they increase the activity of mutated proteins (gain-of-function
mutations), resulting in increased complement activation and exceeding the capacity of regulatory proteins.
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saplotypes include single-nucleotide polymorphisms (SNP) in
he CFH and MCP  gene-promoter region, downregulating FH
nd MCP.  The presence of both polymorphisms in homozygo-
is may provide a rationale for aHUS disposition in patients
ith no mutations in any of the genes associated with aHUS.
 recent collaborative study by the European Working Party
n Complement Genetics in Renal Diseases including 795
atients with aHUS has shown that 3% of these patients were
arriers of combined mutations in more  than one gene. Addi-
ionally, this large study has proved that concomitant risk
aplotypes CFH-H3 and MCPggaac also lead to signiﬁcantly
ncreased disease penetrance in carriers of combined muta-
ions, stressing the idea that genotyping of these risk polymor-
hisms helps predict the risk of aHUS in mutation carriers.61
Along with the previous genetic alterations, a number of
riggering environmental factors are also implicated in the
nset of aHUS. The above mutations are predisposing factors
f the disease, preventing adequate complement regulation in
ell surfaces when the system becomes activated in microves-
els. aHUS is triggered by infectious events in 50–80% ofpatients,11,12,40 particularly those involving the upper respi-
ratory tract (inﬂuenza H1N1 virus). Diarrhoea caused by gas-
troenteritis may precede aHUS in up to 30% of cases (including
diarrhoea by STEC11,12,19).12 Pregnancy, particularly during
post-partum, is a common predisposing factor of aHUS among
women,12,29 together with the use of oral anovulatory agents.
Mutations in the gene coding for thrombomodulin (THBD),
an anticoagulant protein acting as thrombin cofactor and also
regulating the FI-mediated C3b inactivation, have been associ-
ated with aHUS.62 Based on complement dysregulation typical
of patients with aHUS, the functional analysis of THBD muta-
tions associated with aHUS has shown that thrombomodulin
mutations impair the complement regulatory activity.62 Nev-
ertheless, the impairment of the anticoagulation activity by
thrombodulin mutations associated with aHUS and the rel-
evance of these abnormalities in aHUS remains unknown.
In this regard, a recent study conducted in 36 patients with
aHUS has assessed the presence of mutations in the genes
of the complement system and coagulation through mas-
sive DNA sequencing, detecting mutations in genes from both
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Table 2 – Clinical outcome of patients with atypical haemolytic uraemic syndrome based on complement abnormalities
(prior to Eculizumab).
Gene Risk of death or ESRF in
the ﬁrst episode or
within the next year
Risk of relapse Risk of death or ESRF at
3–5 years
Risk  of relapse following
renal transplant
CFH 50–70% 50% 75% 75–90%
CFI 50% 10–30% 50–60% 45–80%
MCP 0–6% 70–90% 6–38%a <20%
C3 60% 50%  75% 40–70%
CFB 50% 3/3 without ESRF 75% 100%
THBD 50% 30% 54%a 1 patient
Anti-FH 30–40% 40–60% 35–60%a Higher with increased
antibody titres
Anti-FH: anti-complement factor H antibodies; CFB:  complement factor B gene; CFH:  complement factor H gene; CFI:  complement factor I gene;
ESRF: end-stage renal failure; MCP:  membrane cofactor protein gene; THBD:  thrombomodulin gene.
a Data on ESRF.
Adapted from Loirat and Fremeaux-Bacchi.1systems.63 The gene in the coagulation system with the largest
number of mutations was plasminogen (PLG), a cymogene
which plays an important role in ﬁbrinolysis following con-
version to plasmin. Even though these data suggest that coag-
ulation genes may add to aHUS disposition (particularly PLG),
further studies are required to conﬁrm these observations.
The search of new genes associated with aHUS has also
been addressed by Lemaire et al.21 through exome sequenc-
ing. The authors have identiﬁed homozygotic mutations in the
DGKE gene coding for the DGK- protein in 13 patients with
aHUS from 9 families. These patients had a very early onset
of aHUS, generally within their ﬁrst year of life, followed by
multiple recurrences and common progression to end-stage
renal failure in the second decade of life.21 Deﬁciency of DGK-
 in endothelial cells has been recently shown to induce the
expression of ICAM-1 and tissue factor by means of increased
p36-MAPK-mediated signalling, leading to apoptosis, altering
the angiogenic response, and determining a proinﬂammatory
and prothrombotic phenotype. Yet, the absence of DGK- is
not detrimental to complement activation in cell surfaces.21,22
The absence of DGK- in podocytes and endothelial cells
may probably impair the diaphragm of glomerular ﬁltration,
which would account for massive proteinuria and the sus-
ceptibility to glomerular conditions among these patients,21,23
although the reason why these patients tend to develop sev-
eral glomerular conditions remains uncertain. Finally, despite
the role of the complement in the development of renal dis-
ease among carriers of DGKE, mutations had been initially
ruled out,21 patients with DGKE mutations additionally asso-
ciated with other genes previously related to aHUS, including
THBD and C3,64 have been recently identiﬁed, thus suggesting
that complement dysregulation may play a role in the modu-
lation of disease onset and outcome at least in some carriers
of DGKE mutations.Prognosis
The availability of Eculizumab has signiﬁcantly revolutionised
the prognosis of patients living with aHUS, a very severedisease in most cases in spite of intensive treatment with
plasma therapy (PT; Table 2). Following a ﬁrst episode of aHUS,
overall mortality was higher than 10% and more  than half
of the patients required dialysis and/or developed a more
permanent renal damage in the next 12 months.11,12,20 The
clinical outcome changes relatedly depending on the patient’s
mutation. In this respect, outcome seemed to be particularly
poor in patients with FH and C3 mutations, with mortality
and end-stage chronic renal failure (ESCRF) rates over 50%
within one year from the ﬁrst episode of aHUS. Furthermore,
half of these patients relapsed. Mutations in FI, FB, and THBD
were also associated with high rates of mortality and ESCRF
at one year (50%), with relapses occurring in nearly one in
3 patients overcoming the ﬁrst episode of aHUS. On the
other side, less than 10% of patients with MCP  mutations
died or progressed to ESCRF, although the risk of relapse
among these patients was higher and up to 90% of them
developed new episodes of aHUS. Between 50 and 75% of
patients with mutations in FH, CI, C3, FB or THBD died or
developed ESCRF within 3–5 years from the ﬁrst episode of
aHUS.1
Recurrence  of  atypical  haemolytic  uraemic  syndrome
following  renal  transplantation
The outcome of renal transplantation (RT) among patients
with ESCRF due to aHUS has been historically limited by the
increased percentage of recurrences of post-transplant dis-
ease (∼50%; graft loss rate: 80–90%65,66), although it changes
signiﬁcantly based on the type of alteration. In a series of 57
patients with aHUS receiving RT, 5-year recurrence-free graft
survival was signiﬁcantly lower in patients with mutations
in the genes coding for complement proteins compared
to patients in whom only polymorphisms but no genetic
abnormalities were found.67 Yet, it should be stressed that
the risk of recurrence of aHUS following RT in patients with
no genetic abnormalities is also deemed high. 68 Mutations
in FH are associated with a higher risk of recurrence or
graft loss following RT (75–90%; speciﬁcally those related to
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Table 3 – Diagnostic tests and procedures recommended for patients with thrombotic microangiopathy.
General diagnostic tests
• Complete medical records, including drugs, data from systemic diseases, personal and family history
• Complete physical examination, including a fundoscopic exam
• General routine blood and urine tests
• Haptoglobin levels
• Serum complement levels
• Peripheral blood smear
• Serology for systemic diseases (ANA, anti-ADN, ANCA, antic-Scl-70, anticentromere)
• Anti-cardiolipin antibodies and lupus anticoagulant
• Serology for HIV, HCV, HBV, CMV and H1N1
• Complete clotting test, with ﬁbrinogen, ﬁbrinogen degradation products and dimer D
• Investigations for typical HUS-causing bacterial infections and Shiga toxin test (if clinically suspected)
Speciﬁc diagnostic tests
• STEC infection • Faecal sample in case of diarrhoea or rectal culture: STEC cultures (MacConkey for E. coli O157:H7); PCR for Stx genes O157:H7 and other
serotypes, and other virus characteristics; ELISA and/or Vero cell tissue culture assay for Stx serum: anti-LPS antibodies for prevalent serotypes
• Pneumococcal infection • Bacterial culture (generally) of sterile body ﬂuids; DAT (Coombs test), viral test (respiratory), chest x-ray (pleural effusion as a characteristic in
most cases), cytochemistry, and CSF culture in cases to pneumococcal meningitis
• Altered regulation of the complement • C3, C4 (plasma/serum), AH50
• FH, FI, FB (plasma/serum)
• Anti-FH autoantibodies
• Expression of superﬁcial MCP in leukocytes (poly- or mononuclear leukocytes using a FACS test)
• Mutation analysis in FH, FI, MCP, C3, FB ± THBD
• ADAMTS13 deﬁciency (acquired or hereditary) • Plasma activity of ADAMTS13 or dose (ELISA) ± inhibitor
• Cobalamin metabolism: methylmalonic aciduria •  Amino acid chromatography in plasma/urine (hyperhomocysteinemia, hypomethioninemia; homocystinuria); organic acid chromatography in
urine (methylmalonic aciduria)
• Mutation analysis for the gene MMACHC
ADAMTS13: A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13; ANA: antinuclear antibody; ANCA: Autoantibodies to neutrophil cytoplasmic antigens; CMV:
cytomegalovirus; CSF: cerebrospinal ﬂuid; DAT: direct antiglobulin test; DNA: deoxyribonucleic acid; ELISA: enzyme-linked immunoabsorption assay; FACS: ﬂuorescence activated cell sorting; FB:
complement factor B; FH: complement factor H; FI: complement factor I; HIV: human immunodeﬁciency virus; HUS: haemolytic uraemic syndrome; MCP: membrane cofactor protein; STEC: Shiga
toxin-producing Escherichia coli;  THBD: thrombomodulin; VHB: hepatitis B virus; VHC: hepatitis C virus.
Speciﬁc diagnostic tests: adapted from Loirat et al.2
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Table 4 – Differential diagnosis between disseminated
intravascular coagulation and thrombotic
microangiopathy.
DIC TMA
Platelet count ↓  ↓
Fibrinogen ↓ Normal
Fibrinogen degradation products ↑ Normal
Dimer D ↑ Normal
Antithrombin ↓ Normal
Schistocytes Present Present
Haptoblogin Normal ↓
Coagulation times Long Normal
Blood pressure ↓ ↑
DIC: disseminated intravascular coagulation; TMA: thrombotic
microangiopathy.430  n e f r o l o g i a. 2
abnormalities in terminal 3′ and gene conversion between
CFH and CFHR1,  resulting in the hybrid gene CFH/CFHR1 [both
abnormalities impair the functionality of the C-terminal
domain of FH]), posing a high risk with mutations in C3
and FI as well (40–80%; Table 2).12,42,48,65,67,69–71 To date, very
few transplants have been performed in patients with FB
mutations, though recurrence of aHUS and graft loss were
reported in all cases.49,72 In general, plasma factors of the
complement involved in aHUS are synthesised in the liver,
and so patients with mutations in the complement genes
coding for these factors remain prone to aHUS following RT,
as dysfunctional factors are still being produced. MCP is a
transmembrane protein that is highly expressed in the kidney
and, as a result, this defect can be corrected by RT by deliver-
ing unchanged MCP  into the graft. Over 80% of patients with
MCP mutations develop no recurrence of aHUS following RT,
with a long-term survival rate comparable to that of patients
receiving transplants for other reasons.40,65,66 The risk of post-
transplant recurrence in patients with THBD62 mutations or
anti-FH antibodies is not well-established, although it seems
to be related to high and persistent titres of antibodies in the
latter.19,73
Diagnosis  of  atypical  haemolytic  uraemic
syndrome
In light of the rapid evolution and the severity of TMA, a
differential diagnosis should be immediately established
from the syndrome perspective, allowing for supportive mea-
sures to be taken within 24–48 h from patient’s admission.
Considerations for an aetiological diagnosis of TMA will sub-
sequently be made. Table 3 summarises the major procedures
and diagnostic tests recommended for the diagnosis of TMA,
including speciﬁc tests for companion diagnostics of the
various aetiologies of TMA.
In patients with TMA, tests results include thrombo-
cytopenia (platelet count <150,000/mm3 or decrease >25%
from baseline)20 and microangiopathic haemolytic anaemia
(haemoglobin <10 mg/dl with a negative direct Coombs test
[though some patients with pneumococcal or H1N1-related
HUS may show positive direct Coombs test],25 elevated LDH,
decreased haptoglobin, reticulocytosis, and schistocytes).20,62
In a retrospective series of 50 patients with histological TMA,
44% had a normal platelet count.74 Consequently, diagno-
sis of TMA  should be considered in patients with renal
failure and elevated LDH, but without thrombocytopenia.
For schistocytes, even though they can be found in most
patients with renal disease, preeclampsia or mechanic valves,
TMA  can be diagnosed with a schistocyte count >1% pro-
vided that there are no other known causes.75 In contrast,
the absence of schistocytes does not rule out a diagnosis
of TMA.
High levels of serum creatinine, low glomerular ﬁltration
(GF) or the presence of proteinuria and/or haematuria11,20,69
are indicative of renal failure. A renal biopsy may be required
for adult patients following acute renal failure to determine
the aetiology, rule out other processes, and assess progno-
sis, although the indication and time for biopsies must be
examined individually in patients with suspected TMA dueto the risk of bleeding. In this sense, diagnostic renal biop-
sies are not recommended in patients conclusively diagnosed
with aHUS (positive family history, recurrence, etc.). Among
paediatric patients, the diagnosis is essentially made on the
basis of clinical presentation, though renal biopsy may occa-
sionally be required (especially in cases of secondary TMA or
RT). Patients with clinical suspicion of TMA  should always
be examined by a nephrologist in light of the urgent treat-
ment strategy required to ensure minimum irreversible renal
damage.
Disseminated intravascular coagulation (DIC) is a syn-
drome that may be associated with several major laboratory
and clinical ﬁndings related to TMA. DIC is characterised
by a systemic activation of coagulation, secondary to sev-
eral clinical conditions (sepsis, trauma or certain tumours),
leading to thrombosis and bleeding, commonly involving
renal function.76 Key test criteria based on coagulation tests
for differential diagnosis of DIC and TMA  are listed in
Table 4.
A complete and detailed clinical history should be made
for TMA  patients, including personal and family history, trigg-
ering factors (drugs, infections), and a thorough physical
examination. As opposed to previous considerations made
several years ago, signs and symptoms of the different types
of TMA are currently thought to be nonspeciﬁc and avoid the
companion diagnostics between these two entities.1 The dif-
ferentiation between HUS and TTP was classically based on
clinical criteria, with HUS and TTP being diagnosed when
renal involvement and neurological involvement were pre-
dominant, respectively. However, 50% of patients with TTP
develop renal failure and 50% of patients with aHUS develop
neurological abnormalities.37,77
Clinical features do not allow for a differentiation between
STEC-HUS and aHUS as well, given that up to 30% of aHUS
cases are developed following gastroenteritis12 or patients
develop diarrhoea42 (a typical symptom of STEC-HUS). On
the other hand, platelet count and the severity of renal
involvement can actually guide companion diagnostics. Over-
all, TTP presents with severe thrombocytopenia (<20,000/mm3
in 73% of patients with acquired TTP)78 and moderate
renal involvement, whereas aHUS usually presents with
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Thrombocytopenia
<150.000 or>25% decrease ±
Microangiopathic haemolysis
Elevated LDH   
Haptoglobin decrease
Schistocytes
Haemoglobin decrease* 
Plus one or more than one of the following
Evaluate ADAMTS13 and Shiga toxin /STEC** test 
TTP
<5-10% ADAMTS13 activity >5-10% ADAMTS13 activity Shiga toxin /STEC positive
aHUS Secondary TMA STEC-HUS***
Neurological symptoms
Confusion 
Seizures
Renal involvement
Elevated creatinine
Decrease in estimated glomerular filtration rate
Urinary changes
Gastrointestinal involvement
Diarrhoea
Nausea/vomiting
Abdominal pain
Gastroenteritis
Fig. 4 – Algorithm for the differential diagnosis of primary thrombotic microangiopathy. ADAMTS13: A Disintegrin And
Metalloproteinase with a ThromboSpondin type 1 motif, member 13; aHUS: atypical haemolytic uraemic syndrome; HUS:
haemolytic uraemic syndrome; LDH: lactate dehydrogenase; STEC: Shiga toxin producing Escherichia coli; TTP: thrombotic
thrombocytopenic purpura. * Negative direct Coombs test. ** The Shiga toxin test/STEC is indicated when the patient has a
history of digestive involvement or gastrointestinal symptoms. *** STEC infection can rarely trigger the underlying disease
activity in some patients with aHUS.
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moderate thrombocytopenia (50–100,000/mm3) and severe
enal involvement. This rule can be deemed a guide, but deter-
ination of ADAMTS13 activity and the Shiga toxin test are
ssential for an accurate differential diagnosis between TTP,
TEC-HUS, and aHUS (Fig. 4). The diagnosis of STEC-HUS can
e conﬁrmed by the presence of the Shiga toxin or a positive
ulture of STEC in patients with TMA,28 while the activity of
DAMTS13 in plasma should be <5–10% in order to conﬁrm
he diagnosis of TTP.79,80 The diagnosis of the remaining cases
hould be directed towards aHUS,79 and so additional tests are
equired to rule out secondary TMAs. Test samples should be
ollected prior to PT.
reatment  options  for  atypical  haemolytic
raemic  syndromereatment for aHUS should involve two different strate-
ies: on one side, supportive treatment measures aimed at
anaging the consequences of aHUS (acute renal failure,high blood pressure, anaemia, thrombocytopenia, etc.), and a
targeted therapy to halt and revert TMA. Speciﬁc options for
the management of aHUS will be reviewed in this section.
Plasma  therapy
PT can be delivered as plasma infusion (PI) and plasma
exchange (PE). In PI, patients are given virus-inactivated,
non-native fresh frozen plasma (FFP), adding functional com-
plement regulators.81 In PE, a patient’s plasma is replaced
with FFP, which not only results in the administration of
high doses of complement-regulating proteins, but also in
the elimination of dysfunctional endogenous soluble comple-
ment inhibitors, minimising the risk of volume overload. In
addition, anti-FH antibodies are also cleared in PE, together
with potential inﬂammatory/thrombogenic factors involved
in endothelial damage and platelet hyperaggregation. The
treatment of choice recommended for episodes of aHUS tra-
ditionally consisted of early and intensive PE at high volumes
and of variable frequency based on disease activity. PIs are
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Table 5 – Prognosis of patients with atypical haemolytic
uraemic syndrome treated with plasma infusion or
plasma exchange.
Remission Death or
end-stage renal
failure
CFH 63% (complete: 5%;
partial: 58%)
37%
CFI 25% (complete:
12,5%; partial: 12,5%)
75%
C3 57% (complete: 43%;
partial: 14%)
43%
THBD 88% (complete: 62%;
partial: 25%)
13%
Anti-FH antibodies 75% (complete: 25%;
partial: 50%)
NA
MCP 97% of treated
patients (complete:
90%; partial: 7%) y
100% of non-treated
patients
NA
Anti-FH: anti-complement factor H antibodies; CFH:  complement
factor H gene; CFI:  complement factor I gene; MCP:  membrane
cofactor protein gene; NA: not available; complete remission:
haematological and renal function normalisation; partial remis-
sion: haematological normalisation and renal sequels; THBD:
thrombomodulin gene.
Adapted from Noris et al.12
dialysis, or both, per patient/day), renal function, quality ofusually ineffective except in a few patients with complete
deﬁciency of FH82 (circulating levels of complement proteins
are normal in most patients). Overall, PT is not considered
effective in patients with isolated MCP  mutations, as this is
a non-circulating protein attached to the cell membrane, with
virtually all patients relapsing following an episode of aHUS
irrespective of the use of PT.12
Even though no prospective clinical trials are available,
PT has empirically been the treatment of choice in aHUS
for years as mortality in patients with TTP-HUS decreased
over the last 3 decades. Table 5 summarises the results
of the largest international registry of PT in patients with
aHUS (International Registry of Recurrent and Familial HUS/TTP),
including 273 patients diagnosed between 1996 and 2007.12
Complete haematological and renal recovery rates with PT in
this registry are generally below 50% (except for patients with
mutations in THBD and MCP), and particularly low rates in
patients with mutations in FH and FI (5 y 12.5%).12 Mortality
and/or outcome of ESRF are generally high in 3 out of 4 patients
with FI mutations. Some papers prove that early intensive PE is
essential to prevent patients from developing aHUS, and main-
tenance can prevent disease recurrence and ESRF,11,81 though
the most effective management strategy is still not known,
nor is the long-term impact on renal function.
Concomitant immunosuppression and PT may improve
outcomes in patients with anti-FH antibodies.19,83,84 High
antibody titres are correlated with a higher risk of relapse and
renal sequels in these cases.19 Even though further trials are
required to conclude on how anti-FH antibodies are devel-
oped by patients with aHUS, the fact that the vast majority;3 5(5):421–447
of these patients have complete deﬁciency of FHR1 leads
to the idea that these antibodies are really targeted against
the FHR1 protein, and that the anti-FH activity is a cross
reaction resulting from the remarkable homology existing
between these 2 proteins. This possibility is a warning of the
potential anti-FHR1/anti-FH sensitisation in homozygotes for
CFHR3-CFHR1 deletion by the exposure to exogenous FHR1,
discouraging the use of PI in these individuals.
The potential complications of PI are anaphylactic reac-
tions to FFP, hypervolemia, high blood pressure, heart failure,
or hyperproteinaemia. The main complications of PE are
obstructed venous access (6%), low blood pressure (5%), and
allergy (4%)85, with a higher frequency among paediatric
patients.85 A study conducted in 71 paediatric patients with
aHUS (59 treated with PE) showed that 80% of children had
some renal sequels within one month of follow-up, 17%
were dialysis-dependant, and 31% developed catheter-related
complications.86
Eculizumab
Eculizumab is a humanised monoclonal IgG2/4 kappa anti-
body that binds to the C5 complement protein with high
afﬁnity, blocking the excision into C5a and C5b, and pre-
venting the formation of the C5b-9 complex of the terminal
complement (membrane attack complex) (Fig. 3).4 In aHUS,
the dysregulation of the alternative complement pathway
leads to the uncontrolled activation of C5, causing a damage
to self structures via the formation of the membrane attack
complex. This process is rapidly and sustainably reduced as
a result of the blockade of the terminal complement pathway
by Eculizumab. A large number of patients with aHUS have
shown a good clinical response to the drug (Table 6).
The efﬁcacy and safety of Eculizumab in aHUS were ini-
tially assessed in two phase II, prospective, multicentre trials,
including 37 patients older than 12 years of age and with
primary or recurrent disease following RT, who received
Eculizumab for 26 weeks, followed by long-term extension
periods.5 Seventeen patients with aHUS (mean time from
diagnosis: 9.7 months) with evidence of progressive TMA  fol-
lowing ≥4 sessions of PT the week before their inclusion
(C08-002) were enrolled in the ﬁrst study. The second study
recruited 20 patients (mean time from diagnosis: 48.3 months)
receiving PT (1 session every 2 weeks and 3 sessions a week)
where no decrease >25% was reported in platelet count for
at least 8 weeks prior to ﬁrst dosing of Eculizumab (C08-
003). Genetic or anti-FH antibody mutations were observed
in 76% and 70% of patients from the ﬁrst and the sec-
ond study, respectively. Primary outcomes in both studies
were: (a) inhibition of complement-mediated TMA  (study 1:
increased platelet count; study 2: TMA-free patient ≥12 weeks
[no decrease in platelet count >25%, no PT and no dialysis]),
and (b) haematological normalisation (≥2 normal consecu-
tive measurements of platelets and LDH, with a minimum
interval of 4 weeks). Secondary outcomes included change
in the rate of daily interventions for TMA  (PI or PE sessions,life, safety and tolerability. Primary outcomes reported at 26
weeks and in extension studies are described in Table 7. With
regard to primary outcome, following 26 weeks of treatment,
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Table 6 – Published cases of patients with atypical haemolytic uraemic syndrome receiving Eculizumab (last updated in
April 2014).
Patients with aHUS in native kidneys
Reference Mutation Response to plasma
therapy
Baseline serum
creatinine, mol/l
Patient outcome Last serum
creatinine value,
mol/l
121,122 Unidentiﬁed Resistant to plasma
exchange
265  Remission after 3
years
35
123 CFH Partially sensitive to
plasma exchange
80 Remission after 10
weeks
26
124 a Unidentiﬁed Resistant to plasma
exchange
690  Recurrence after 2
weeks
End-stage renal
failure
125 a Unidentiﬁed Resistant to plasma
exchange
∼310  Recurrence after 2
weeks
End-stage renal
failure
126 CFH S1191L V1197A Resistant to plasma
infusion
108  Remission after 15
months
44
127 CFI
p.A258 T
Resistant to plasma
exchange
610  Remission after 7
months
230
38,128 b Unidentiﬁed No plasma therapy 600 Remission after 6
months
125
129 CFH
C611Y
Intolerance to
plasma exchange
∼230 Remission after 24
months
∼100
130 Unidentiﬁed Resistant to plasma
exchange
∼325  (dialysis) Remission after 9
months
∼80
131 CFH Resistant to plasma
exchange
∼310  (dialysis) Remission after 18
months
∼75
132 MCP
c.286+ 1G>C
Resistant to plasma
exchange
Dialysis Haematological
normalisation
End-stage renal
failure
133 Unidentiﬁed Resistant to plasma
infusion
Continuous
hemodiaﬁltration
Remission  after one
year
18
134 CFH
3355 G>a;
Asp1119Asn; SCR19
Resistant to plasma
exchange
Dialysis Remission > 2.5 years 26
43  a Unidentiﬁed Sensitive to plasma
exchange
Dialysis Resolution of
thrombocytopenia
and skin lesions
Dialysis
135 CFH Partially sensitive to
plasma exchange
723 (dialysis) Remission Dialysis-free
136  c Unidentiﬁed − ∼247 (dialysis) Remission after 6
months
Dialysis-free
137 C3 Resistant to plasma
therapy
Dialysis Remission after 2
years
Dialysis
138 CFH
3514G>T
Resistant to plasma
therapy
∼222  (dialysis) Remission after one
year
117
139 C3
c3466G>A
Resistant to plasma
exchange
Dialysis Remission > 11
months
115
140  a C3 – Dialysis Remission Dialysis-free
141  c CFB
c.967A>C;
p.Lys323Gln
–  20 Favourable outcome
at 6 months, in spite
of the persistence of
slightly increased
plasma levels of LDH
y C5b-9
Normal levels
142 CFH
p.Arg53Cys; c.157C.T
Resistant to plasma
exchange
Normal levels Remission Normal levels
143  c CFH
p.Lys1186Thr
CFI
p.Ile322Thr
Partially sensitive to
plasma exchange
Dialysis Remission 75
144 CFI
c.786delA
Resistant to plasma
exchange
Dialysis Remission 88
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Table 6 – (Continued )
Renal transplant patients
Preventive use of Eculizumab
Reference Mutation Previous transplants
(number)
Response to plasma
therapy
Baseline serum
creatinine, mol/l
Patient outcome Last serum
creatinine level,
mol/l
107 CFH W1183C No Sensitive to plasma
exchange
∼45  No recurrence 44
108 CFH E1198stop No No plasma therapy Dialysis No recurrence Normal
109 CFH/CFHR1
hybrid gene
No Sensitive to plasma
exchange
Dialysis No recurrence 80
110 CFH/CFHR1
hybrid gene
No Sensitive to plasma
exchange
Dialysis No recurrence Normal
111 CFH/CFHR1
hybrid gene
No No plasma therapy Dialysis No recurrence 79
112 CFH c.3497C9T No Resistant to plasma
exchange
Dialysis No recurrence 76
Use of Eculizumab for the treatment of post-transplant aHUS recurrence
145  a CFH Y475S Yes (1) Resistant to plasma
exchange
132  Graft loss NS
146,147 C3 R570Q Yes (1) Sensitive to plasma
exchange
320  2 recurrences in
cases
of delayed
Eculizumab
230
97 Unspeciﬁed No Resistant to plasma
exchange
323  Remission 238
98 CFH S1191L Yes (2) Intolerance to
plasma exchange
131  Remission 130
148  a Unidentiﬁed No Resistant to plasma
exchange
415  Graft loss NS
42 CFH Yes (1) Resistant to plasma
exchange
500  Remission 62
69 C3 R570W Yes (2) Partially sensitive to
plasma exchange
220  Remission 115
99 CFH
E3514Stop
No  Partially sensitive to
plasma exchange
565  (dialysis) Remission 229
149 Unidentiﬁed Yes (1) Resistant to plasma
exchange
449  (dialysis) Recurrence 5
months following
withdrawal of
Eculizumab. Graft
loss
NS
43 CFH No Partially sensitive to
plasma infusiond
220 Remission
(disappearance of
skin lesions)
209
aHUS: atypical haemolytic uraemic syndrome; CFB:  complement factor B gene; CFH/CFHR1:  complement hybrid gene resulting from CFH/CFHR1
conversion; CFH:  complement factor H gene; CFHR1: complement factor H-related protein 1 gene; CFI:  complement factor I gene; HUS: haemolytic
uraemic syndrome; LDH: lactate dehydrogenase; TMA: thrombotic microangiopathy; NE: not speciﬁed.
a Receiving only one dose of Eculizumab.
b Reduced dose of Eculizumab.
c Early use of Eculizumab (≤7 days following diagnosis of aHUS).
d Suspected persistence of TMA activity due to the presence of ulcerative skin lesions in lower limbs.in study 1 treatment with Eculizumab was associated with
a signiﬁcant increase in the number of platelets from base-
line (p < 0.001) and a rate of haematological normalisation of
76%. In study 2, 80% of patients were free of TMA episodes
following 26 weeks of treatment with Eculizumab and 90%
had haematological normalisation. In terms of secondary out-
comes, treatment with Eculizumab at 26 weeks was associated
with a signiﬁcant reduction in the rate of daily interventionsfor TMA vs. baseline (p < 0.001), as well with a continuous
improvement of estimated GFR (+32 ml/min/1.73 m2 [p = 0.001
vs. baseline] and +6 ml/min/1.73 m2 [p < 0.001 vs. baseline]
in studies 1 and 2, respectively), a decrease in proteinuria
(p < 0.05) and a reduced need for dialysis. Also, the earlier
Eculizumab is introduced in trials (less time of evolution
between the clinical manifestation of aHUS and the drug),
the more  signiﬁcant the improvement of the estimated GFR
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Table 7 – Main results from prospective studies with Eculizumab in patients with aHUS.
C08-002 (n = 17) C08-003 (n = 20) C10-003 (n = 22) C10-004 (N = 41)
Week 26 Week 64 Week 100 Week  26 Week 62 Week 156 Week 26 Week 26
Change in platelet count from baseline (×109/l), mean
p value vs. baseline
+73a
<0.001
+91
0.001
+97
<0.0001
+5
NS
NA NA +164
<0.0001
+135
<0.0001
Platelet count normalisation,b number of patients (%) 14 (82) 15 (88) NA NA NA NA 21 (95) 40 (98)
No TMA events,c number of patients (%) 15 (88) 15 (88) 15 (88) 16 (80)a 17 (85) 19 (95) 21 (95) 37 (90)
Haematological normalisation (complete
haematological response)d, number of patients (%)
13  (76) 15 (88) 15 (88) 18 (90) 18 (90) 18 (90) 18 (82) 36 (88)
Daily intervention rate for TMAe (number of
events/patients/day)
Before Eculizumab, mean
On Eculizumab, mean
p value vs. “before Eculizumab”
0.88
0
<0.001
0.88
0
<0.001
NA  0.23
0
<0.001
0.23
0
<0.001
NA NA NA
Complete response for TMA,f number of patients (%) 11 (65) 13 (76) NA 5 (25) 7 (35) NA 14 (64)a 30 (73)a
Outcome of estimated GFR (ml/min/1.73 m2)
p value vs. baseline
+32
0.001
+32
<0.001
+38
≤0.05
+6
<0.001
+9
0.003
+4
NS
+64
<0.0001
+29
<0.0001
Reduction ≥ 25% in serum creatinine, number of
patients (%)
11  (65) 13 (76) 13 (76) 3 (15) 7 (35) 11 (55) 16 (73) NA
Increased estimated GFR ≥ 15 ml/min/1.73 m2, number
of patients (%)
8  (47) 9 (53) 10 (59) 1 (5) 3 (15) 8 (40) 19 (86) 22 (54)
No dialysis, number of patients/number of patients in
dialysis at the start of treatment (%)
4/5 (80) 4/5 (80) NA 0/2 (0) 0/2 (0) NA 9/11 (82) 20/24 (83)
Improvement in CRD in at least one stage, number of
patients (%)
10  (59) 11 (65) 13 (76) 7 (35) 9 (45) 12 (60) 17 (77) 26 (63)
Reduction of proteinuria in at least one grade in
patients with baseline proteinuria grade ≥ 1, number
of patients/total number of patients
12/15 9/11 NA 6/11 7/9 NA NA NA
Improvement in quality of life (change in questionnaire
scoring), meang
p value vs. baseline
+0.32
<0.001
+0.30
<0.001
+0.29
<0.0001
+0.10
<0.001
+0.13
<0.001
+0.16
≤0.001
+19.7
<0.0001
+0.23
0.003
aHUS: haemolytic uraemic syndrome; CRD: chronic renal disease; EQ-5D: EuroQoL Group 5-Dimension Self-Report Questionnaire; FACIT-F: Functional assessment of chronic illness therapy-fatigue;
GFR: glomerular ﬁltration rate; LDH: lactate dehydrogenase; NA: not available; NS: not signiﬁcant; PE: plasma exchange; PI: plasma infusion; TMA: thrombotic microangiopathy.
a Primary outcome.
b Platelets ≥150 × 109/l.
c No platelet decrease > 25%; no plasma therapy and no start of dialysis for ≥12 weeks.
d ≥2 normal consecutive measurements of platelets and LDH, with at least 4 weeks apart.
e Plasma PI or PE sessions, dialysis, or both, per patient/day.
f Complete haematological response and decrease ≥25% in serum creatinine from baseline (two consecutive measurements with at least 4 weeks apart).
g The EQ-5D questionnaire was used in all studies, except for C10-003 study, where the FACIT-F questionnaire for paediatric patients was used.
Adapted from Legendre et al.,5 Delmas et al.,87 Gaber et al.,88 Fakhouri et al.90 and Greenbaum et al.91
 0 1 5
aHUS and a continuous risk of TMA and potential organ
92436  n e f r o l o g i a. 2
(p < 0.05). The results of extension trials at 1 and 3 years
prove that long-term treatment with Eculizumab is associ-
ated with maintenance or progressive improvement of the
haematological response and renal function.87,88 All these
positive results with Eculizumab were observed irrespec-
tively in patients with or without genetic or anti-FH antibody
abnormalities.
Overall, tolerability of Eculizumab was good, and severe
treatment-related adverse effects were only reported in 4
patients in each study, probably in the context of the back-
ground condition, aHUS (study 1: malignant hypertension,2
severe hypertension, and asymptomatic bacteriuria; study
2: inﬂuenza infection, peritonitis, venous sclerosis at the
time of the infusion, and fever Q). Increased risk of infec-
tion by encapsulated germs, especially Neisseria meningitides,
results from the mode of action of Eculizumab, and so
all patients were vaccinated against Neisseria (tetravalent
vaccine) 14 days before treatment and/or received antibi-
otics, with no reports of meningitis. Only one patient
died of digestive bleeding 3 years later (unrelated to
Eculizumab).
The safety and efﬁcacy of Eculizumab during pregnancy
has recently been studied in patients with paroxysmal
nocturnal haemoglobinuria. Data from 61 women with 75
pregnancies while on treatment with Eculizumab suggest a
good tolerability proﬁle of Eculizumab during pregnancy, with
high rates of foetal and maternal survival (96% and 100%,
respectively). Eculizumab was observed in 7 out of 20 blood
samples of umbilical cord and in none of the 10 samples of
human milk.89
Two phase III, multicentre, prospective, open-label trials
of Eculizumab in aHUS are currently ongoing, one in adult
patients (n = 41; C10-004)90 and the other in paediatric patients
91(n = 22; C10-003 22). Unlike previous trials, these new studies
primarily involve patients who have been recently diagnosed
with aHUS (73%). In the adult trial, mean time from diagnosis
Established suspition of aHUS
Monitor the treatment
Paediatric patient: 
Start eculizumab earlier as treatment of cho
±
Support treatment
Adult patient*: 
Start eculizumab early (perform early and intense
starting it, if it is this that could delay it)
 ±
Support treatment
Fig. 5 – Treatment for atypical haemolytic uraemic syndrome. PE
syndrome. * When the diagnosis of aHUS is unequivocal (positiv
renal transplant), Eculizumab should be use earlier as treatment;3 5(5):421–447
to inclusion was ∼3 weeks, whereas mean time from clinical
onset to Eculizumab was 2 weeks (15% of patients had not
been treated with PT prior to Eculizumab).90 The paediatric
trial involves patients with aHUS ≤18 years with a mean time
from diagnosis to inclusion of ∼2 weeks and a mean time
from clinical onset to Eculizumab of ∼1 week (55% had not
been treated with PT).91 Results from these 26-week trials
conﬁrm the signiﬁcant haematological and renal function
improvements seen in previous studies, as well as the beneﬁts
of early use of Eculizumab (Table 7).90,91 The safety proﬁle
was similar, although two patients developed meningococcal
meningitis (5%) in the adult study. Both infections were
well-managed, and one of the patients continued treatment
with Eculizumab. Survival in patients from both studies
was 100%.
Blood samples from adult patients enrolled in the C10-
004 trial were collected at baseline (before treatment with
Eculizumab) and in subsequent visits up to Weeks 49–54
in order to measure the impact of Eculizumab on biomark-
ers related to TMA and endothelial damage in aHUS.92
Patients with aHUS (irrespective of the presence or absence
of related mutations, PT, or haematological values) showed
activated complement system and inﬂammation, coagula-
tion, activation, endothelial damage, and renal injuries prior
to treatment. Eculizumab led to normalisation of comple-
ment activation-related biomarkers and signiﬁcantly reduced
biomarkers of inﬂammation, thrombotic risk, endothelial
and organic damage. Eculizumab also reduced biomark-
ers related to the activation of the alternative complement
pathway and endothelial activation, although they did not
completely return to normal. These ﬁndings underline the
persistent chronic of complement activation in patients withdamage.
There is also a retrospective study including 19 paediatric
patients with aHUS receiving Eculizumab in a clinical setting
•  Draw blood specimens before
   starting the treatment for
   subsequent studies. 
•  Meningococcal
   vaccination
   ± Antibiotic prophylaxis
ice
 PEs until
: plasma exchange; aHUS: atypical haemolytic uraemic
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or a mean time of 28 weeks (C09-001).3 Eighty nine percent
f patients in this study had a normalised platelet count and
8% remained free of TMA  episodes, although most of them
ere under haematological remission with prior treatment
ith PE. The rate of interventions for TMA was reduced
rom 0.3 per patient/week to 0 (p < 0.0001). GFR increased
o ≥15 ml/min/1.73 m2 in 47% of patients and 50% required
o dialysis at all. Pyrexia (47%), diarrhoea (32%), and upper
espiratory tract infections (32%) were the most common
dverse effects.
ecommendations  for  the  management  of  the
typical  haemolytic  uraemic  syndrome
ver since Eculizumab was approved for the treatment
f aHUS by the EMA  and the Spanish Agency for Drugs
nd Health Products (AEMPS) in 2011,3 management and
rognosis among patients with aHUS have substantially
mproved, as the drug was approved for use as ﬁrst-line
herapy. Recommendations for the treatment of aHUS made
y the authors of this document based on available evi-
ence and cumulative clinical experience are summarised
elow.
reatment  of  atypical  haemolytic  uraemic  syndrome
n view of technical difﬁculties of PT in paediatric patients
by body size) and potential complications, in addition to
he superiority of Eculizumab for the recovery of renal func-
ion (and the resulting improved prognosis), early ﬁrst-line
reatment with Eculizumab is highly recommended in this
opulation, therefore avoiding the use of PE. Consequently,
arly administration of Eculizumab is recommended as
reatment of choice in ﬁrst line in paediatric patients with
uspected aHUS (Fig. 5).91 Eculizumab should be initiated ear-
ier in adult patients with suspected aHUS following PE.90 PE is
nly recommended in adults when diagnosis is unclear. The
se of Eculizumab may only be disregarded in patients with
aematological complete recovery and improved renal func-
ion following PE. In this study, the aHUS French Study Group
ecommended switching the patient to Eculizumab if platelet
ount or LDH levels do not return to normal following the ﬁfth
E, or reducing plasma creatinine ≥25%.93 Eculizumab is the
reatment of choice recommended whenever the diagnosis
f aHUS is unequivocal (positive personal or family history or
isease recurrence following RT). Early administration ensures
eversibility of haematological parameters and prevents renal
njuries.
All patients should be vaccinated against N. meningi-
ides (preferably with conjugate tetravalent vaccines against
erotypes A, C, Y, and W135, and serotype B) prior to treat-
ent with Eculizumab. If treatment with Eculizumab cannot
e delayed until vaccine response, associated treatment with
ntibiotics against N. meningitides may be initiated and antibi-
tic prophylaxis may be established3 as per the hospital pro-
ocol. Given the higher frequency of invasive meningococcal
nfection among paediatric patients, and the absence of
erotype B protection (currently the most prevalent following
ystemic vaccination in the population for other serotypes),(5):421–447 437
this age group should continue to use antibiotic prophy-
laxis, including penicillin or amoxicillin, in combination with
Eculizumab,2 although these prophylaxis protocols may be
adjusted following the recent availability of the new serotype
B vaccine. The maintenance of antibiotic prophylaxis in adult
patients receiving Eculizumab is at the physician’s own discre-
tion and should be individually assessed. Continued antibiotic
prophylaxis should be considered in immunodepressed
patients receiving Eculizumab as a result of the lower response
to the vaccine among these patients (particularly among
those receiving renal transplants). In paediatric patients,
Haemophilus inﬂuenzae and pneumococcal vaccines are also
required, together with strong compliance of local effec-
tive recommendations on compulsory vaccines for each age
group.
If response to Eculizumab is good, treatment should be
maintained indeﬁnitely as recommended in the summary of
product characteristics.3 No recommendations can be made
so far on the right treatment duration, though increasing expe-
rience with drug use may help better deﬁne this as well as
treatment strategies in the future.
Withdrawal and/or individual dose titration of Eculizumab
may be considered for speciﬁc cases, but only among low-risk
patients (with isolated mutation in MCP  and negative family
history), always individually and following at least 12 months
of treatment.94,95 Patients who withdraw treatment as per
clinical indication should be carefully monitored for at least
12 weeks for potential abnormalities suggestive of TMA  and/or
relapse.3,96 In these patients immediate readministration with
Eculizumab should be considered.3,96
Eculizumab should be maintained for at least 3 months in
patients with aHUS and acute renal failure requiring dialysis
in order to assess the improvement of renal function. Pro-
gressive increase of diuresis with good pressure management
are positive parameters guiding the management of the TMA
process and improvement of renal injuries. Renal biopsies
in patients receiving dialysis may help decision-making
associated with treatment continuation. If treatment fails
in patients and they still require dialysis for renal failure,
Eculizumab should be withdrawn, except in patients with sys-
temic disease manifestations, where treatment continuation
should be assessed individually.
Whenever PT is considered for a patient with aHUS,
PE should preferably be performed with FFP replacement
(1.5 per plasma volume [60–75 ml/kg] per session to add
complement factors). Sessions should be performed until
platelet count returns to normal, end of haemolysis ends,
and sustained improvement of renal function for several
days occurs. Five weekly sessions should be conducted there-
after for the ﬁrst 2 weeks and 3 weekly sessions for the
next 2 weeks, while PE continuation should be individually
assessed.2,82
Patients with aHUS who develop anti-FH antibodies while
on PT should use concomitant immunosuppressants to pre-
vent antibody formation.19,73,83,84 Treatment response among
these patients should be monitored based on the outcome of
antibody titres.73General supportive measures are necessary to ensure
acceptable conditions for patients until TMA  is managed.
High blood pressure is common among patients with aHUS
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Table 8 – Differential diagnosis of TMA  in renal transplant patients.
TMA de novo Recurrence of aHUS
History of HUS/TMA No Yes
Systemic involvement No Common
Intensity of clinical picture Mild Severe
Onset Progressive Sudden
Intensity of haematological TMA Low High
Causative/triggering agents CNI, mTORiViral infectionsHumoral rejection Triggering factors are not always found
Reversibility Yes No. Graft loss
aHUS: atypical haemolytic uraemic syndrome; CNI: calcineurin inhibitors; HUS: haemolytic uraemic syndrome; mTORi: mammalian target of
Rapamycin inhibitors; TMA: thrombotic microangiopathy.
Adapted from Zuber et al.68and should be treated with angiotensin II blockers (ACEI
or AIIRA). Volemic control is also vital due to common
hypervolemia and acute risk of pulmonary oedema. Trans-
fusions of red blood cells concentrates and/or the use of
erythropoiesis-stimulating factors should be considered for
the treatment of anaemia. Platelet transfusions should be
reserved for cases of severe low platelet counts (<30,000/mm3)
or exceptionally for severe bleeding and/or prior to invasive
procedures with risk of bleeding, as the TMA phenomenon
may become worse. Potential agents leading to aHUS should
also be identiﬁed and managed. Paediatric patients with
aHUS should be referred to specialised centres for paedi-
atric nephrology including expert staff and an intensive care
unit for paediatric patients in order to ensure adequate
treatment.
Atypical  haemolytic  uraemic  syndrome  and
transplantation
Treatment  for  the  recurrence  of  atypical  haemolytic  uraemic
syndrome  in  renal  transplantation
Primary clinical criteria for the differential diagnosis of
the different types of TMA  in RT and an algorithm for the
management of these entities are described in Table 8
and Fig. 6, respectively. Diagnosis in patients receiving
renal transplantation and developing TMA, with a his-
tory of aHUS episodes before transplantation, should be
directed to disease recurrence (ruling out other potential
causes).
Treatment for the recurrence of aHUS in patients receiv-
ing renal transplants should be performed under the
same terms as in aHUS of native kidneys by means of
the early use of Eculizumab.5,42,43,69,90,91,97,100 In view of
the induced immunosuppression status of transplanted
patients (chronic immunosuppression), vaccination against
N. meningitides is also recommended to assess the main-
tenance of antibiotic prophylaxis while on treatment with
Eculizumab.
In patients with progressive TMA  in the ﬁrst study of
Eculizumab, renal function recovery following administration
was signiﬁcantly improved in the long term in nontrans-
planted patients (with aHUS in native kidneys) compared
to patients receiving renal transplantation.5 This result maybe related to the fact that transplanted patients enrolled in
the study received Eculizumab later than nontransplanted
patients (mean time from clinical onset to enrolment: 1.71
and 0.67 months for both types of patients, respectively). This
observation stresses the need to early use Eculizumab for
aHUS recurrence in RT.
Prophylaxis  for  the  recurrence  of  the  atypical  haemolytic
uraemic  syndrome  following  renal  transplantation
Perspectives of RT in patients with ESRF secondary to aHUS
receiving dialysis have signiﬁcantly changed in recent years,
especially in patients with high risk of disease recurrence
following transplantation (patients with risk mutation and/or
relapse of aHUS). The use of Eculizumab has made treatment
options available for these patients for whom RT was con-
traindicated because of the high rate of relapse and the risk of
renal graft loss. There are currently three treatment options
to prevent aHUS recurrence following RT: (a) a liver–kidney
combined transplantation; (b) simple RT together with
prophylaxis with PT, and (c) simple RT with prophylactic
Eculizumab.
Over 20 cases of patients with aHUS and mutations in
genes coding for complement factors primarily synthesised
in the liver (FH, FB or FI) and receiving liver transplants
(isolated or combined with RT) have been recently reported
so as to avoid the consequences of the genetic defect and
prevent disease recurrence. This strategy, combined with
the perisurgical use of Eculizumab or plasma (to eliminate
dysfunctional complement factors during surgery and add
enough functional factors until liver function is recovered),
was successful in several occasions, with good liver func-
tion and no recurrence of aHUS during follow-up.70,101–105
Nonetheless, given the potential morbi-mortality related to
liver transplants,2 and the challenge posed by the availabil-
ity of organs and safer alternatives, liver–kidney transplants
should only be considered in selected patients with aHUS as
a second option. Isolated liver transplants are also not rec-
ommended for patients with aHUS and functional kidneys, as
chronic immunosuppression risks outweigh risks related to
68long-term use of Eculizumab.
Prophylaxis with PT in patients with ESRF secondary to
aHUS and receiving simple RT has been associated with pos-
itive outcomes in terms of disease recurrence prevention in
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everal papers.68 Yet, recurrence of aHUS has been reported
ollowing RT in patients at risk, including the use of inten-
ive PT.68,100 On the other hand, factors including the potential
ncreased risk of disease recurrence with progressive spacing
f PT sessions106 or the impact on QoL in patients result-
ng from long-term PT (mostly related to sustained vascular
ccess) are restrictive of this strategy.68
Several positive experiences with the use of prophylaxis
ith Eculizumab among paediatric patients receiving FH
rior to RT from a cadaveric donor have been reported in
he last years (Table 6),107–111 therefore suggesting that RT
ssociated with prophylactic Eculizumab is an effective and
ell-tolerated option for these patients.68 Zuber et al.100 have
ecently published a series including 9 patients receiving pro-
hylaxis with Eculizumab for aHUS recurrence following RT.100
his series involves 6 paediatric patients and 3 adults with
arious mutations in the alternative complement pathway (5
n FH, one in C3 and 3 patients with hybrid genes resulting
rom the non-homologous recombination between CFH and
FHR1). Two patients receiving post-RT PE were later switched
o Eculizumab, two patients received Eculizumab from the
eek before transplantation (unrelated living donor; urgent
ransplant from cadaveric donor) and the remaining 5 received
culizumab immediately following transplantation. The other patients had a positive outcome without recurrence fol-
owing a mean follow-up of 14.5 months (mean creatinine:
1.6 ± 44.8 mol/l), except for one case of early thrombosis
AHR
TMA in a renal transplanted patien
anaemia + thrombopenia +
De novo
Viral infection
(CMV, virus BK)
Drugs
(CNI, mTORi)
Aetiological treatment
± PEs
Modification IS
± PEs
Evaluate Eculizumab
in resistant cases
ig. 6 – Treatment for thrombotic microangiopathy in renal trans
nhibitors; mTORi: mTOR  inhibitors (mammalian target of Rapam
icroangiopathy; AHR: acute humoral rejection; PE: plasma exch
aemolytic uraemic syndrome; STEC: Shiga toxin-producing Esch
ransplantation is very rare.(5):421–447 439
leading to graft loss. Blasco Pelicano et al.112 reported the ﬁrst
use of prophylactic Eculizumab in our country in an adult
female patient with FH mutation and a favourable outcome,
without signs of relapse following 3 years of RT.112 Patients
with ESRF secondary to aHUS who are eligible for RT should
therefore use prophylactic Eculizumab as a ﬁrst option for the
prevention of aHUS recurrence following transplantation.68,93
Fig. 7 includes an algorithm for the previous assess-
ment and management of aHUS patients who  are eligible
for RT.
There are also positive experiences on liver–kidney
transplants using prophylactic Eculizumab,105 although as
explained before, liver–kidney transplants should be consid-
ered as a second option for selected patients with aHUS.
Living donor transplants have traditionally been con-
traindicated in patients with aHUS in view of the high rates of
disease recurrence and graft loss, and the risk of undetectable
mutations in the complement system of the donor poten-
tially resulting in the subsequent development of aHUS.1,66,113
Progress made so far in the ﬁeld of genetic diagnosis and the
availability of Eculizumab allow for consideration of related
living donor transplantation as a valid option for patients with
aHUS. A complete genetic-molecular exam should always
be performed in donors, who will only be eligible based on
mutations identiﬁed in the patient and absent in the donor.
However, if the related donor and the recipient share any
genetic factor of susceptibility to aHUS, or if no mutations
   Aetiological treatment
± PEs
aHUS
Recurrence
t (non-immune haemolytic
 graft dysfunction) 
STEC-aHUS
Eculizumab
early
plantation. CMV:  cytomegalovirus; CNI: calcineurin
ycin); IS: immunosuppression; TMA: thrombotic
ange; HUS: haemolytic uraemic syndrome; aHUS: atypical
erichia coli. a STEC-HUS recurrence following renal
440  n e f r o l o g i a. 2 0 1 5;3 5(5):421–447
Low risk of aHUS recurrence after KT 
Patient with CTKD secondary to aHUS
candidate for KT
Moderate-high risk of aHUS recurrence after KT 
-  Mutations in CFH, CFI C3, CFB
-  CFH/CFHR1 Hybrid gene Combined mutations
-  Mutation unidentified /  with unknown effect 
-  Persistence of anti-FH antibodies 
-  Previous recurrence of aHUS (in an affected individual or family)
-  With no mutation but with CFH polymorphisms
- Isolated mutations in MCP
- DGKE mutation
- Undetectable-FH antibodies
•   Complement study.a 
•   DGKE study if the HUS
     was produced in the first
     year of life 
Cadaveric donor
With Living
unrelated donor
Cadaver donor 
With Living unrelated
donor.b
Living related
donor
Living related
donor
Unable to perform 
KT with related 
living donor
Unable to perform
KT with related
living donor
Yes
KT with no prophylaxis
No Yes No
KT with eculizumab prophylaxis
as first option
The mutation indisputably
associated with the pathogenesis
of an aHUS in the recipient
not found in the donor
The mutation indisputably associated 
with the pathogenesis of an aHUS in 
the recipient not found in the donor
Eculizumab is available 
Fig. 7 – Recommendations for the management of patients with ESRF secondary to aHUS who are eligible for RT. Adapted
from Zuber et al.68 aHUS: atypical haemolytic uraemic syndrome; CFB: complement factor B gene; CFH/CFHR1: complement
hybrid gene resulting from CFH/CFHR1 conversion; CFH: complement factor H gene; CFHR1: complement factor H related
protein 1; CFI:  complement factor I gene; DGKE:  Diacylglycerol Kinase, Epsilon 64 kDa; ESRF: end-stage chronic renal failure;
FH: complement factor H; MCP: membrane cofactor protein gene; RT: renal transplantation. CKTD: chronic terminal kidney
disease; KT: kidney transplant. a Determination of plasma levels of C3, C4, FH, FI and FB, as well as MCP  expression in
peripheral leukocytes; complete genetic study to detect known complement mutations (and risk polymorphisms), together
with screening for anti-FH antibodies. b RT with an unrelated living donor will only be considered if Eculizumab is available.are observed both in the recipient or the donor, no genetically
matched living donor transplantation should be performed.93
Also, a living donor transplantation should only be considered
if Eculizumab is available.
No speciﬁc protocols based on prospective trial on
immunosuppression to reduce the risk of post-RT relapse
are available. In general, calcineurin inhibitors114 and mTOR
inhibitors68,115 are thought to be related to post-RT TMA, with
a synergic effect in the combination of both drugs.116 These
drugs should therefore be carefully used in patients receiving
renal transplants due to ESRF secondary to aHUS. Guidelines
on immunosuppression based on belatacept could be fol-
lowed depending on the immunological risk of each patient,
although no conclusive data are available in the literature as to
the best immunosuppressive strategy for the risk population.Conclusions
• aHUS results from genetic or acquired dysregulation of the
activated alternative complement pathway on cell surfaces
leading to systemic TMA. Several mutations and polymor-
phisms have been described in recent years in genes from
certain complement factors associated with this dysregula-
tion.
• Clinical presentation comprises the triad of nonimmune
microangiopathic haemolytic anaemia, thrombocytopenia,
and acute renal dysfunction, associated with common
extra-renal manifestations. Before Eculizumab became
available, aHUS was generally associated with increased
mortality and/or progression to ESRF, as well as to increased
recurrence following RT.
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Although unnecessary to the clinical diagnosis of aHUS, a
research of the complement including plasma levels of all
Table 9 – Protocol for sample collection for complement
tests in patients with atypical haemolytic uraemic
syndrome.
• If samples are to be sent to a reference laboratory, we
strongly recommend to contact the laboratory before and
follow the instructions on samples required for assays
• If no reference laboratory is available and samples are to be
stored for further tests, samples to be collected are:
• 10 ml of blood with EDTA
• 10 ml of coagulated blood for serum
• If a patient is a young child and 20 ml of blood cannot be
drawn, 2–3 ml can be collected from each of the samples
(6–9 ml in total)
• Blood with EDTA must be immediately centrifuged at
3000 rpm for 10 min at 4 ◦C followed by plasma collection in
a clean tube, taking care so as not to absorb any red cells.
After labelling 5 tubes with the patient’s name, the date, and
an indication showing EDTA plasma, plasma collected from
these tubes should be distributed, freezing them
immediately and keeping them at a temperature of −80 ◦C
• Once plasma was drawn, store the cellular pellet frozen at
−80 ◦C for future DNA collection
• Coagulated blood for 1 h at room temperature should be
centrifuged at 3000 rpm for 10 min at 4 ◦C and the serum
should be immediately separated, taking care so as not to
absorb any red cells in the clean tube. Following labelling of
5 tubes with the patient’s name, the date, and an indication
showing serum, serum collected from these tubes should ben e f r o l o g i a. 2 0 
 Diagnosis should point to aHUS if TMA is clinically sus-
pected and provided that the Shiga toxin/STEC test is
negative, plasma ADAMTS13 is >5–10% and if secondary
forms of HUS have been ruled out.
 Eculizumab is a monoclonal antibody inhibiting C5 acti-
vation and the formation of the membrane attack
complex, responsible for damage to self structures in
aHUS. In prospective studies including patients with aHUS,
Eculizumab effectively prevented the TMA process and was
associated with long-term signiﬁcant haematological and
renal function improvements.
 The authors of this paper recommend the early use of
Eculizumab for aHUS in paediatric and adult patients with
clinically suspected aHUS in native kidneys, and aHUS
recurrence following RT or post-RT de novo aHUS.
 Prophylaxis with Eculizumab is recommended for the pre-
vention of aHUS recurrence in patients with secondary ESRF
receiving RT from a living or cadaveric donor.
 Eculizumab should be considered in patients with sec-
ondary TMA  refractory to usual treatment.
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Annex  1.  Recommendations  for  the  treatment
of  secondary  forms  of  haemolytic  uraemic
syndrome
The management of secondary forms of HUS should be based
on the treatment of the primary aetiology of the disease and
the administration of PE. As explained, there is an increas-
ing number of reports in the literature from patients with
secondary HUS showing good response to Eculizumab, there-
fore suggesting that the complement plays an important
role in the development of TMA in certain patients with
secondary HUS.30–34,117–120 Consequently, the potentially tem-
poral administration of Eculizumab should be considered as
salvage therapy in selected patients with secondary HUS
refractory to initial treatment measures. Also, screening for
complement gene mutations in patients with secondary HUS
points out that the underlying disease is actually aHUS, and
so these patients should be treated as per the guidelines
described in “Recommendations for the management of the
atypical haemolytic uraemic syndrome”.
Annex  2.  Recommendations  of  interest  for  the
diagnosis  of  genetic  abnormalitiesdistributed, freezing samples immediately after and
maintaining them at −80 ◦C
EDTA: ethylenediaminetetraacetic acid.
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factors should be conducted, together with a complete genetic
analysis of all affected patients. Samples should be collected
prior to treatment initiation, including plasma exchange,
and should be sent to a reference laboratory (Table 9). As
mutations have been identiﬁed in the complement sys-
tem of patients with secondary STEC-HUS and HUS, genetic
tests should also be individually conducted in these patients
to study the potential association with complement/aHUS
abnormalities.2
Genetic diagnosis of complement genes is generally recom-
mended as it allows for individualised estimates of prognosis
and risk of disease recurrence. Genetic tests are essential for
patients who may be eligible for RT.
A Working Group coordinating and providing online coun-
selling on complement tests for aHUS patients has been set
up in order to collect data and conduct further trials.
Graft samples from renal transplant patients with aHUS
should be collected for future studies.
Annex  3.  Recommendations  for  the
determination  of  ADAMTS13
Table 10.
Table 10 – Protocol for collection and shipping of
samples for determination of ADAMTS13 activity.
• Collect blood by venopuncture in two 5 ml citrate tubes
• Label tubes with patient’s name and last name, date, and
time of collection
• Centrifuge tubes for 7 min at 3500 rpm
• Transfer supernatant (plasma) to Eppendorf’s tubes for
aliquots. Avoid transferring part of the precipitate (results
may be altered). Samples must not be frozen before this step
• Label new tubes with the same information
• Freeze tubes at −20 ◦C and send them to a reference
laboratory. Also send a 5 ml EDTA tube (refrigerated)
ADAMTS13: A Disintegrin And Metalloproteinase with a Throm-
boSpondin type 1 motif, member 13; EDTA: ethylenediaminetetra-
acetic acid.
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